Immunoprecise Antibodies Ltd
XTSX:IPA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Petronas Chemicals Group Bhd
KLSE:PCHEM
|
MY |
|
Iwaki Co Ltd
TSE:6237
|
JP |
|
C
|
Crescendo Corp Bhd
KLSE:CRESNDO
|
MY |
|
Hanwei Electronics Group Corp
SZSE:300007
|
CN |
|
E
|
Electra Ltd
TASE:ELTR
|
IL |
|
Saint Marc Holdings Co Ltd
TSE:3395
|
JP |
|
Acreage Holdings Inc
OTC:ACRDF
|
US |
|
J
|
Jiangsu Zenergy Battery Technologies Group Co Ltd
HKEX:3677
|
CN |
|
Aquis Exchange PLC
LSE:AQX
|
UK |
Immunoprecise Antibodies Ltd
Operating Income
Immunoprecise Antibodies Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Operating Income
-CA$6.9m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Operating Income
-$217.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Operating Income
-CA$39.4k
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Innovotech Inc
XTSX:IOT
|
Operating Income
CA$23.9k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
Immunoprecise Antibodies Ltd
Glance View
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia and currently employs 73 full-time employees. The firm is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The firm offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies.
See Also
What is Immunoprecise Antibodies Ltd's Operating Income?
Operating Income
-6.9m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Operating Income amounts to -6.9m CAD.
What is Immunoprecise Antibodies Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
-13%
Over the last year, the Operating Income growth was -69%. The average annual Operating Income growth rates for Immunoprecise Antibodies Ltd have been -13% over the past three years .
